NEW YORK, March 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Research Objectives•Understand trends, dynamics, and parameters specific to the delivery of drugs to cancer patients in key treatment settings such as home, office, or infusion center. •Identify physician prescribing trends relative to drug delivery considerations. •Understanding the role of reimbursement in physician's choice of drug delivery. •Identify physicians' perception of different drug delivery approaches, as well as key drivers for adoption/non-adoption, compliance, and choice of delivery devices. •Identify drug delivery trends within the oncology area. •Determine product attributes relative to delivery that are considered to be important by physicians and patients. •Identify prospective patient preferences and willingness to try new technologies as well as determine key drivers of adoption/non-adoption. Industry Background
Drug delivery is an important area of drug development in the pharmaceutical and biotechnology industry. In oncology, developers are interested in understanding the opportunities and parameters for delivery of drugs in outpatient settings, particularly in the home. This is important for biotechnology products used in this area as companies seek to design new products and evaluate new opportunities for targeted therapies and other cancer treatments. Scope: Drug Delivery Categories
The eleven drug delivery categories evaluated in this research are:•Intravenous injection •Subcutaneous (SC) injection •Intramuscular (IM) injection •Intravenous infusion •Implantable infusion pump •External infusion pump •Transdermal patch •Topical gel or cream •Implant •Oral •Rectal Executive Summary
•Across all cancer types, oral is currently the dominant ( percent) mode of drug delivery. Meanwhile, the availability and prescription of effective implantable infusion pump as an oncology drug delivery mode has the potential for higher patient acceptance compared to external infusion pump. However, a significant proportion ( percent) of patients who are unwilling to use external infusion pumps will still comply if the method is prescribed by a doctor.•While cancer patients are least familiar with topical gel or cream for oncology treatment, percent of respondents reported that they would be willing to use this method for future oncology treatments, implying a potential for high growth rate.